No Data
Express News | Akebia Therapeutics Shares Are Trading Higher After HC Wainwright & Co. Maintained a Buy Rating on the Stock and Raised Its Price Target From $6 to $7.5
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Raises Price Target to $7.5
Akebia Therapeutics Analyst Ratings
Express News | Akebia Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $7.5 From $6
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets
Earnings Call Summary | Akebia Therapeutics(AKBA.US) Q2 2024 Earnings Conference